Home / Intelligence / White Papers / What Lies Ahead for New Product Launches?
Trinity Life Sciences has been tracking and analyzing the challenges of commercialization and new product launches in the Biopharma industry for years (see our 2022 white paper, Empowering the Next-Generation Launch Model). One method we have leveraged to track the challenges in commercialization is new product launch performance, comparing first calendar year actual sales with consensus Wall Street analyst forecast estimates at time of launch for novel product (New Molecular Entities) launches within the U.S.
In this white paper, we explore historical launch performance trends to help predict where launches are headed and what the industry needs to be thinking about to improve commercialization success.
Complete the form below to access the full white paper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
White Papers
Moving the Needle: Lessons from the 2023 Launch Class
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
Read More
Briefs
The “Molecular Optimizer” Archetype: A Strategy for First-Launch Companies to Streamline Their Path to Market
The “molecular optimizer” archetype is a strategy utilized by first-launch companies to optimize existing molecules when developing their first product. Companies using this approach tend to be small and emerging biotech firms that are seeking a foothold to enter the market. The primary benefit of this approach is that the method offers a higher probability […]
Read More
Webinars
Picking Winners: Portfolio Management for a New Era
Available On Demand
Did you know 62% of products launched between September 2019 and December 2021 underperformed expectations in the first year of launch? What is going wrong, and how can we get it right? Join Trinity Life Sciences for a thought-provoking webinar to dive into the first white paper in our Industry Impact Series, Picking Winners: Portfolio Management for […]
Watch Now